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Resumen
La creación de bancos de sangre del cordón umbilical (UCB), plantea interesantes 
problemas médicos, sociales, económicos y éticos. Este documento analiza los 
problemas éticos en particular. En este sentido, se evalúa: a) si hay ventajas en el uso 
de la UCB en comparación con la médula ósea, b) si es o no es ético crear bancos 
de SCU, c) si su creación es éticamente aceptable en términos de su utilidad clínica 
o d) el uso de los mismos con fines terapéuticos, y finalmente, e) si su creación está 
éticamente justificada desde el punto de vista costo / rentabilidad. Nos centramos 
principalmente en la evaluación de la controversia ética entre los bancos públicos y 
privados, y en particular sobre si es ético almacenar sangre autóloga en bancos de SCU 
privados, sobre la base de sus limitadas posibilidades de uso por parte del donante 
de sangre del cordón umbilical. Desde el punto de vista ético, se puede concluir que 
los bancos de sangre autóloga tiene una limitada aceptación entre investigadores 
especializados, sociedades científicas y otras instituciones públicas, por lo que nos 
parece, que es éticamente más adecuado apoyar la creación de bancos públicos de 
SCU, por razones médicas y sociales y, sobre todo basado en el principio de justicia y 
solidaridad humana. Sin embargo, no hay ningún argumento ético definitivo por qué 
una pareja, de acuerdo con su autonomía y libertad, no puede almacenar la SCU de 
su hijo en un banco privado. Una solución igualmente aceptable podría se la creación 
de bancos mixtos, como el propuesto por Virgin Health Bank o como los españoles 
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en donde las muestras autólogas se pueden almacenar en bancos públicos, pero con 
la condición de que si en un momento determinado la muestra almacenada fuera 
requerida por otra persona ajena al donante, habría que dársela.
Palabras clave: bancos de sangre de cordón umbilical, bancos públicos de sangre 
de cordón umbilical, bancos privados de sangre de cordón umbilical, aspectos éticos.
Abstract
The creation of umbilical cord blood (UCB) banks raises interesting medical, social, 
economic and ethical issues. This paper reviews the ethical problems specifically. 
In this respect, it evaluates: a) whether there are advantages to the use of UCB 
compared to bone marrow, b) whether or not it is ethical to create UCB banks, c) 
whether their creation is ethically acceptable in terms of their clinical usefulness or d) 
the use made of them for therapeutic purposes, and finally e) whether their creation 
is ethically justified from a cost/profitability point of view. We focus primarily on 
evaluating the ethical controversy between public and private banks, particularly on 
whether it is ethical to bank autologous blood in private UCB banks, on the basis of 
its limited possibilities for use by the cord blood donor. We can conclude that, from 
an ethical point of view, autologous blood banks have limited acceptance among 
specialised researchers, scientific societies and other public institutions. Therefore, 
we believe that it is ethically more acceptable to support the creation of public UCB 
banks for medical and social reasons and, above all, based on the principle of justice 
and human solidarity. Nevertheless, there is no definitive ethical argument why a 
couple, according to their autonomy and freedom, cannot bank their child’s UCB in 
a private bank. An equally acceptable solution could be the creation of mixed banks, 
such as that proposed by the Virgin Health Bank or like the Spanish system where 
autologous samples can be stored in public banks but with the proviso that if at any 
time the stored sample is required by any person other than the donor, it would have 
to be given to them.
Key Words: Umbilical cord blood banks. Public umbilical cord blood banks. Private 
umbilical cord blood banks. Ethical aspects.
a result, this type of biological material 
is being increasingly used in clinical 
medicine1. This therapeutic reality 
aroused our interest in the ethical 
evaluation of the use of UCB, especially 
1 Wagner JE, Gluckman E «Umbilical cord 
blood transplantation: The first 20 years.» Seminars 
in Hematology 4, (2010); 3-12.
1. Introduction
Since the first umbilical cord blood 
(UCB) transplant was carried out in 1988, 
UCB has been known to be a useful source 
of stem cells for treating patients who 
require transfusions of haematopoietic 
material, both children and adults. As 
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the ethical aspects related with both types 
of existing UCB banks: public and private.
2. Ethical aspects related with UCB 
banks
Several aspects can be considered on 
assessing the ethicality of the creation of 
UCB banks: 1) whether their creation and 
maintenance is clearly ethical, regardless 
of whether they are public or private, 2) 
the ethicality of public versus private 
banks, 3) various general ethical aspects 
related with the rights of donors and 
their children.
2.1. Is it ethical to create UCB banks, either 
public or private?
The first ethical aspect to consider is 
whether it is necessary at present to create 
UCB banks, either public or private. 
From a clinical point of view, it is not 
always possible to find a histocompatible 
relative who can donate UCB to treat 
another family member who requires this 
treatment, since only 30% find a matching 
donor 2, thus making it necessary to 
develop other alternatives. Among these, 
the ideal solution is to create allogeneic 
HPC banks, i.e. from people unrelated 
to the patient requiring transplantation.
To carry out this evaluation, four 
fundamental aspects can be considered: 
1. Advantages and disadvantages 
of the use of UCB in relation to 
bone marrow (BM) and G-CFS 
2 Sullivan MJ «Banking on cord blood stem 
cells» Nature Reviews Cancer 8, (2008), 554-563. 
mobilized peripheral blood from 
fully matched and haplo-identical 
donors.
2. Ethical justification for the creation 
of UCB banks in terms of their 
clinical usefulness.
3. Ethical justification for their 
creation in relation to their use, 
i.e. whether they are used to the 
extent previously hoped for.
4. Ethical assessment of the cost 
effectiveness of the storage and use 
of the conserved samples. 
2.1.1. Ethical assessment of the use of 
UCB with respect to BM. Advantages and 
disadvantages
The first question that can be asked 
is if, in view of the large number of duly 
identified BM samples that currently exist 
(now in excess of 18 million), it is also 
necessary to promote the conservation 
of UCB samples, and if so, what reasons 
might there be for this? Therefore, we 
consider it imperative to first evaluate 
whether the use of UCB offers advantages 
over the use of BM, since if this is the 
case, regardless of the large number of 
BM samples that already exist in specific 
donor registers, the conservation of UCB 
samples would also be justified.
According to Wagner and Gluckman, 
in a review of the first 20 years of umbilical 
cord blood transplantation3, the following 
were confirmed advantages of UCB;
a) the absence of any risk for the UCB 
donor and the lower risk of transmission 
3 Wagner JE, Gluckman E, op.cit. 1.
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of an infection by pathogens for the 
recipient.
b) banked HLA-typed UCB was 
immediately available; c) UCB collections 
could be targeted, a potential strategy 
for overcoming the under-representation 
of many ethnic and racial minorities 
plaguing most adult volunteer donor 
registries.
Other «benefits», however were more 
speculative than known, namely: a) UCB 
would contain enough hematopoietic 
stem and progenitor cells to engraft 
most adults and children; b) UCB would 
be associated with less graft-versus-
host disease (GVHD) as the neonate 
is immunologically «naïve»; c) HLA 
matching would be less stringent, again 
because of the immunological naiveté, 
although these benefits are already well 
established.
Nonetheless UCB was also associated 
with potential risks. Interestingly, 
the many opponents of UCB argued 
vehemently that the immunological 
naiveté of UCB would result in higher 
relapse rates and risks of opportunistic 
infection. Other opponents argued that 
maternal cell contamination would 
result in life-threatening acute GVHD. 
However, it would be the high likelihood 
of graft failure that would most severely 
limit the usefulness of UCB, due to the 
low absolute numbers of hematopoietic 
stem cells and progenitors.
In summary, there does not appear 
to be any ethical difficulty in promoting 
the use of UCB together with BM, given 
the potential advantages of UCB with 
respect to BM.
2.1.2. Ethical justification for the creation 
of UCB banks in terms of their clinical 
usefulness
There is no doubt that today the clinical 
usefulness of UCB is widely justified4, 
since it can be used to treat acute and 
chronic leukaemias5,6,7 myelodysplastic 
syndromes8, β-thalassaemia major9,10, 
Fanconi  anaemia 11,12,  s ickle  ce l l 
anaemia13,14,  severe bone marrow 
4 Ibid 1.
5 Laughlin MJ, Eapen M, Rubinstein P et al. 
«Outcomes after transplantation of cord blood or 
bone marrow for unrelated donors in adults with 
leukemia.» New England Journal of Medicine 351, 
(2004), 2265-2267.
6 Advani AS, Laughlin MJ. «Umbilical cord 
blood transplantation for acute myeloid leukemia.» 
Current Opinion in Hematology 16, (2009), 124-128.
7 Atsuta Y, Suzuki R, Nagamura-Inoue T 
et al. «Disease-specific analyses of unrelated cord 
blood transplantation compared with unrelated 
bone marrow transplantation in adult patients with 
acute leukemia.» Blood 113, (2009), 1631-1638.
8 Parikh SH, Mendizabal A, Martin PL et al. 
«Unrelated donor umbilical cord blood transplan-
tation in pediatric myelodysplastic syndrome: a 
single-center experience.» Biology of Blood and Mar-
row Transplantation 15, (2009), 948-955.
9 MacMillan ML, Walters MC, Gluckman 
E «Transplant outcomes in bone marrow failure 
syndromes and hemoglobinopathies» Seminars in 
Hematology 47, (2010), 37-45.
10 Boncimino A, Bertaina A, Locatelli F «Cord 
blood transplantation in patients with emoglobin-
opathies» Transfusion and Apheresis Science 42, (2010), 
277-281.
11 MacMillan ML, Walters MC, Gluckman E, 
op.cit. 9.
12 Gluckman E, Rocha V, Ionescu I et al. «Re-
sults of unrelated cord blood transplant in Fanconi 
anemia patients: risk factor analysis for engraftment 
and survival.» Biology of Blood and Marrow Transplan-
tation 13,(2007), 1073-1082.
13 Ibid 9.
14 Boncimino A, Bertaina A, Locatelli F, op.cit. 
10.
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aplas ia 15 ,16,  lymphopro l i f e ra t ive 
disorders17, severe immunodeficiency 
syndrome18,19, autoimmune diseases20, 
severe metabolic disorders21,22,23 and also 
cancers and other solid tumours24, 25.
This ample potential for clinical 
use appears to ethically justify the use 
of UCB for therapeutic purposes and, 
consequently, the creation of banks of 
this haematopoietic material. 
Similarly, clinical trials currently 
underway in patients with neonatal 
15 Ibid 9.
16 Yoshimi A, Kojima S, Taniguchi S et al. 
«Unrelated cord blood transplantation for severe 
aplastic anemia.»Biology of Blood and Marrow Trans-
plantation 14, (2008), 1057-1063.
17 Gratwohl A, Baldomero H «European sur-
vey on clinical use of cord blood for hematopoietic 
and non-hematopoietic indications» Transfusion and 
Apheresis Science 42, (2010), 265-275.
18 Cairo MS, Rocha V, Gluckman E et al. 
«Alternative allogeneic donor sources for transplan-
tation for childhood diseases: unrelated cord blood 
and haploidentical family donors». Biology of Blood 
and Marrow Transplantation 14, Supplement, (2008), 
44-53. 
19 Smith AR, Gross TG, Baker KS «Transplant 
outcomes for primary immunodeficiency disease.» 
Seminars in Hematology 47, (2010), 79-85.
20 Gratwohl A, Baldomero H, op.cit. 17.
21 Cairo MS, Rocha V, Gluckman E et al., op. 
cit. 18.
22 Beam D, Poe MD, Provenzale JM et al. 
«Outcomes of unrelated cord blood transplantation 
for X-linked adrenoleukodystrophy.» Biology of 
Blood and Marrow Transplantation 13, (2007), 665-674.
23 Escobar ML, Poe MD, Provenzale JM et al. 
«Transplantation of umbilical cord blood in babies 
with infantile Krabbe’s disease.» New England Jour-
nal of Medicine 352, (2005), 2069-2081.
24 Ibid 17.
25 Ibid 18.
brain damage26 and diabetes type 127 
may eventually support the ethicality 
of the use of UCB, although at present 
the results are very tentative and further 
more extensive studies are required to 
confirm them28.
From an ethical point of view, 
regardless of the use of UCB in various 
pathologies, an important aspect to 
consider is whether the results obtained 
could justify its use. In this respect, the 
specialised literature shows that the 
average engraftment when UCB is used is 
75% to 80% for children with leukaemia, 
28% to 78% for adults with leukaemia and 
70% to 80% for non-malignant diseases, 
and that the survival is 49% to 55% for 
children, 75% for adults and 80% for non-
malignant diseases29. However, although 
transplant consolidation is slower when 
UCB is used than with BM, the incidence 
of GVHD is lower with UCB30. Moreover, 
UCB transplant can be carried out with 
26 Cord blood for neonatal hypoxic-ischemic 
encephalopathy Duke University, Clinical protocol: 
NCT00593242 www.clinicaltrials.gov
27 Haller MJ, Viener HL, Wasserfall C at al. 
«Autologous umbilical cord blood infusion for type 
1 diabetes» Experimental Hematology 36 (6), (2008), 
710.
28 Ministero del Lavoro, della Salute e delle 
Politiche Sociali «Uso appropiato delle cellule sta-
minali del sangue del cordone ombelicale» Elementi 
informativi essenziali. 14-05-2009.
29 Kurtzberg J, Lyerly AD, Sugarman J «Un-
tying the Gordian knot: policies, practices, and 
ethical issues related to banking of umbilical cord 
blood» The Journal of Clinical Investigation 115, (2005), 
2592-2597.
30 Rocha V, Wagner JE, Sobocinski KA et al. 
«Graft-versus-host disease in children who have 
received a cord-blood or bone marrow transplant 
from an HLA identical sibling» New England Journal 
of Medicine 342, (2000), 1846-1854.
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fewer matched HLA antigens, although 
ideally at least 5 of the 6 antigens should 
be matched and the UCB units should 
contain not less than 2.5 x 107 nucleated 
cells. When these criteria are met, the 
transplant can be successful in more than 
50% of patients31.
Hence, prominent authors like John 
Wagner and Eliane Gluckman declare 
that «umbilical cord blood has now 
become one of the most commonly used 
sources of hematopoietic stem cells for 
allogeneic transplantation»32.
Therefore, it seems that the use of UCB 
and the creation of banks for this type of 
biological sample, in terms of their clinical 
usefulness, can be ethically justified. 
2.1.3. Ethical justification for the creation 
of UCB banks in terms of their clinical use
An undeniably interesting aspect to 
consider in the ethical justification for the 
creation of UCB banks is whether these 
are clinically used to a sufficient extent.
This appears to be widely justified, 
since from the creation of the first UCB 
bank in New York in 199333, the number 
of samples stored in public banks has 
been gradually growing; thus in 1997 
there were already 11,000 samples, 22,000 
in 1998, 38,000 in 1999, 64,000 in 2000, 
87,000 in 2001, 128,000 in 2002, 165,000 
31 Querol S, Mufti GJ, Marsh SGE et al. «Cord 
blood stem cells for hematopoietic stem cell trans-
plantation in the UK: how big should the bank be?» 
Haematologica 94, (2009), 536-541.
32 Ibid 1.
33 Rubinstein P, Rosenfield RE, Adamson JW 
et al «Stored placental blood for unrelated bone 
marrow reconstruction.» Blood 81, (1993), 1679-1690.
in 2003, 189,000 in 2004, 212,000 in 2005, 
252,000 in 2006, 262,000 in 2007, 339,000 in 
2008, 408,000 in 2009, 450,000 in 2010 and 
456,000 in 2011 (not all years computed)34.
Moreover, their clinical use has also 
gradually increased, as the latest data 
indicate that more than 20,000 units have 
already been utilised for clinical purposes35.
In addition, there are currently more 
than 100 active UCB banks worldwide36 
and the number of hospitals where UCB 
samples can be collected has grown 
substantially. At present there are more 
than 3500 hospitals located in more than 
80 countries authorised to collect UCB 
samples37. 
Consequently, and in accordance with 
all of the above, it seems reasonable to 
accept that the creation of UCB banks is 
ethically justified in terms of the clinical 
use of the samples stored in them.
2.1.4. Ethical assessment of the cost-
effectiveness (cost/ benefit) of the storage 
and use of UCB samples deposited in 
public banks
The first aspect to consider in this 
point is whether the number of samples 
that would be needed to meet the clinical 
requirements of a certain population can 
34 Total number of cord blood units Bone 
Marrow Donors Worldwide (http://www.bmdw.
org/index.php?id=statistics_cordblood)
35 Gluckman E, Rocha V «Cord blood trans-
plantation: state of the art» Haematologica 94, (2009), 
451-454. 
36 Katz G, Mills A «Cord blood banking in 
France: Reorganizing the national network» Transfu-
sion and Apheresis Science 42, (2010), 307-316.
37 Katz G, Mills A, op.cit. 36.
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be reasonably obtained, since if not, it 
would be difficult to ethically justify the 
promotion of this type of facility. In fact, 
it appears that this is easily achievable, 
since it is estimated that 50,000 units 
of UCB would be sufficient to meet 
the needs of a population of around 60 
million inhabitants38. 
Another aspect to consider in this 
field is whether the financial investment 
necessary to reach the number of UCB 
samples required to cover the clinical 
needs of society would be ethical.
If we begin with economic data from 
Spain39, the minimum cost of storage of 
one UCB unit is 1300 €. The maintenance 
cost per year is 40 €. These costs have 
been calculated considering that 50% 
of the units extracted are discarded, 
a percentage that in principle can be 
considered as optimal, but which in many 
cases is not attainable. So, if we consider 
that the percentage of samples discarded 
may increase, it can be concluded that if 
65% are discarded, the storage price for 
one unit will increase to 1600 €, and to 
1900 € if 80% are discarded40. Therefore, 
making an approximate economic 
assessment, with an estimated discard 
rate of 50% and 50,000 units stored, if 
around 200 units are used per year, the 
cost per unit would be around 20,000 €41.
38 Querol S, Mufti GJ, Marsh SGE et al., op.cit. 
31.
39 Plan Nacional de Sangre de Cordón Um-
bilical http://www.ont.es/infesp/Paginas/PlanNa-
cionalSCU.aspx
40 Querol S, Gómez SG, Pagliuca A et al. «Quali-
ty rather than quantity: the cord blood bank dilemma». 
Bone Marrow Transplantation 45, (2010), 970-978.
41 op.cit 39
According to the previous data, the 
minimum cost for storing 50,000 UCB units 
(the amount required to meet the clinical 
requirements of a population of 60 million 
inhabitants) would be around 65 million 
Euros42, assuming a discard rate of 50%. 
Undoubtedly, these costs would have to 
be added to the costs required to prepare 
the hospital logistics necessary for sample 
extraction and delivery to the blood bank. 
Thus, we believe that from a cost/
benefit point of view, the financial 
investment needed to create public blood 
banks that store a sufficient number of 
samples to meet the clinical needs of any 
country would be ethically justified.
2.1.5. How the storage of the sample can 
condition its use
Another technical aspect that must be 
considered, but with undeniable ethical 
repercussions, is to determine the period 
of time that the stored samples can be 
conserved in good conditions for use, 
since if they deteriorate rapidly, their 
storage may not be ethically justified, 
as many would no longer be available 
for use when needed. In this respect, it 
has been shown that properly frozen 
samples in a technically well-equipped 
blood bank can be maintained in good 
conditions for clinical use for at least 15 
years43. Furthermore, in a recent personal 
42 Ibid 39.
43 Broxmeyer HE, Srour EF, Hangoc G et al. 
«High-efficiency recovery of functional hemato-
poietic progenitor and stem cells from human cord 
blood cryopreserved for 15 years» PNAS 100, (2003), 
645-650.
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statement, HE Broxmeyer declared that he 
had been able to verify the conservation 
of UCB samples in good conditions for 
up to 23 years44. In view of the above, it 
appears reasonable to conclude that, from 
an ethical point of view, setting up public 
UCB banks would be justified in relation 
to their creation and maintenance.
3. Ethical controversy between private 
and public banks
Without doubt, one of the most relevant 
ethical aspects in relation to UCB banks is to 
clarify which of them, the public or private, 
should be promoted first and foremost45,46,47. 
This diatribe is also necessary because 
it implies opposing social and personal 
attitudes. In this respect, the main ethical 
controversy centres on whether or not 
it is right to promote and create private 
autologous UCB banks. 
The first point that must be considered 
in assessing the ethics of creating private 
banks is to determine to what extent the 
samples banked there will be able to be 
used in the more or less near future by 
the child donating the cord blood.
44 Broxmeyer HE «Umbilical cord transplanta-
tion: Epilogue» Seminars in Hematology 47, (2010), 
97-103.
45 Fisk NM, Roberts IAG, Markwald R et al. 
«Can routine commercial cord blood banking be 
scientifically and ethically justified?» PLoS Medicine 
2, (2005), 87-90.
46 Ecker JL, Greene MF «The case against 
private umbilical cord blood banking» Obstetrics 
and Gynecology 105, (2005), 1282-1284. 
47 Sugarman J, Kaalund M, Kodish E et al. 
«Ethical issues in umbilical cord blood banking. 
Working group on ethical issues in umbilical cord 
blood banking (review)» JAMA 278, (1997), 938-943.
In relation to this, the first reports 
mentioned in the specialised literature 
estimated a probability of use of between 
1/2700 and 1/20,00048. However, as this 
probability can increase with the life 
of the donor, subsequently calculations 
estimated that the possibility of the donor 
themselves undergoing an autologous 
blood stem cell transplant is 1/2700 
(0.04%) up to age 20 years, 0.10% up 
to age 40 years and 0.25% up to age 70 
years49,50. 
However, a recent study 51 reported 
that in 57 specialised centres in the 
United States and Canada in which UCB 
transplants are carried out, autologous 
UCB was only used on nine occasions. 
A study from the Italian ministry52 
also reported three cases of autologous 
transplants53,54,55. There may be further 
48 Johnson FL «Placental Blood Transplanta-
tion and Autologous Banking-Caveat Emptor.» 
Journal of Pediatric Hematology/Oncology 19, (1997), 
183-186.
49 Nietfeld JJ, Pasquini MC, Logan BR et al. 
«On the probability of using cord blood» Biology of 
Blood and Marrow Transplantation 14, (2008), 724-725.
50 Nietfeld JJ, Pasquini MC, Logan BR et al. 
«Lifetime probabilities of hematopoietic stem cell 
transplantation in the U.S.» Biology of Blood and 
Marrow Transplantation 14, (2008), 316-322.
51 Thornley I, Eapen M, Sung L et al. «Private 
cord blood banking: experiences and views of pedia-
tric hematopoietic cell transplantation physicians» 
Pediatrics 123: 3, (2009), 1011-1017.
52 op.cit. 28.
53 Ferreira E, Pasternak J, Bacal N et al. «Au-
tologous cord blood transplantation» Bone Marrow 
Transplantation 24, (1999), 1041.
54 Fruchtman SM, Hurlet A, Dracker R et al. 
The successful treatment of severe aplastic anemia 
with autologous cord blood transplantation. Biology 
of Blood and Marrow Transplantation 10(11), (2004), 741.
55 Hayani A, Lampeter E, Viswanatha D et al. 
«First report of autologous cord blood transplan-
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unpublished cases, but we can state with 
almost full certainty that the clinical 
use of autologous UCB is currently an 
exception56, since as far as we are aware, 
there is only one case of a duly verified 
autologous UCB transplant, in a four-year 
old girl with acute leukaemia57.
In view of the above, it seems difficult 
to ethically justify the obtaining, storage 
and conservation of autologous UCB 
samples in terms of their probable clinical 
use, given the very low probability that 
they will be used. 
Another important ethical aspect to 
consider in relation to private autologous 
UCB banks is the cost of a transplant 
of this type of haematopoietic material, 
taking into account the number of samples 
currently stored and the transplants 
carried out. There are presently believed 
to be around 800,000 UCB samples 
stored worldwide in private banks58. 
Furthermore, as already mentioned, there 
has only been one proven case of the use 
of autologous UCB59 and some likely 
tation in the treatment of a child with leukemia». 
Pediatrics 119, (2007), 296.
56 Samuel GN, Kerridge IH, O’Brien TA «Um-
bilical cord blood banking: public good or private 
benefit?». The Medical Journal of Australia 188, (2008), 
533-535. 
57 Hayani A, Lampeter E, Viswanatha D et al., 
op.cit. 55.
58 Manegold G, Meyer-Monard S, Tischelli A 
et al. «Controversies in hybrid banking: attitudes of 
Swiss public umbilical cord blood donors towards 
private and public banking» Archives of Gynecology 
and Obstetrics 284, (2010), 99-104. 
59 Ibid 55.
cases60,61,62. Moreover, it is known that 
conserving an autologous UCB sample 
in a technically well-equipped private 
bank for 20 years could cost around 1500 
to 2000 € for banking the sample and 
around 150 € per year for storage63,64, i.e. 
around 3000 €65. Consequently, storing 
those 800,000 UCB samples for 20 years 
could cost approximately 2,400 million 
Euros. We must therefore ask ourselves, 
is this financial investment to likely treat 
a single patient (and certainly less than 
a dozen) ethical?
In relation to this high cost however, it 
can be argued that the investment required 
to store and conserve the aforementioned 
autologous UCB samples in private banks 
is defrayed by the parents of the child 
donating the UCB. Therefore, they have 
the right to decide how to spend their 
money, especially if they use it to aid 
the possibility, albeit remote, of treating 
a son or daughter if necessary, bearing in 
mind the legitimate right of individuals to 
dispose of their own financial resources 
as they deem most fit, following the most 
elementary principles of the right to the 
use and enjoyment of private property 
as one of the fundamental guarantors of 
individual liberties. Even so, we are of 
the opinion that private money also has a 
60 Thornley I, Eapen M, Sung L et al., op cit. 51.
61 Ferreira E, Pasternak J, Bacal N et al., op.cit. 
53.
62 Fruchtman SM, Hurlet A, Dracker R et al., 
op. cit. 54.
63 Kurtzberg J, Lyerly AD, Sugarman J, op. 
cit. 29.
64 Annas GJ. «Waste and Longing- The Legal 
Status of Placental-Blood Banking» The New England 
Journal of Medicine 340, (1999), 1521-1524.
65 Sullivan MJ , op.cit. 2
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social function, and that consequently we 
would have to ask ourselves if those 2,400 
million Euros, even though they come 
from individuals, could not have been 
used for another more appropriate social 
purpose, even within the healthcare field.
3.1. Medical disadvantages of using autolo-
gous UCB samples
In addition to their limited possibility 
for clinical use and low cost-effectiveness, 
the use of autologous UCB also has 
some medical contraindications, as 
chromosomal translocations have been 
shown in the foetal blood of children who 
later developed leukaemia66,67,68.
Therefore, the American Academy of 
Pediatrics has declared that the use of 
autologous UCB may be contraindicated 
due to the risk of transferring the 
aforementioned genetic abnormalities to 
the child receiving the transplant69,70.
The various difficulties discussed up to 
this point have meant that the creation of 
private autologous UCB banks is prohibited 
in several countries71, so to resolve this legal 
66 Zipursky A «Fetal origin of leukemia and 
autologous cord blood transfusions.» Pediatric Re-
search 47, (2000), 574.
67 Rowley JD «Backtracking leukemia to birth» 
Nature Medicine 4, (1998), 150-151.
68 Greaves MF, Wiemels J «Origins of chromo-
some translocations in childhood leukaemia» Nature 
Reviews Cancer 3, (2003), 639-649.
69 Leonard MB «Glucocorticoid-induced 
osteoporosis in children: Impact of the underlying 
disease» Pediatrics 119: Supplement 2, (2007), 166-174. 
70 Lubin BH, Shearer WT «Cord blood bank-
ing for potential future transplantation» Pediatrics 
119, (2007), 165-170.
71 Thornley I, Eapen M, Sung L et al., op. cit. 
51.
problem, some parents have chosen to send 
the extracted samples for conservation to 
countries in which the creation of private 
autologous UCB banks is authorised.
3.2. Could other clinical applications for 
autologous umbilical cord blood extend its 
clinical use?
We have seen that autologous UCB 
samples do not have many possibilities 
of being used for future haematopoietic 
transplant for the child donating the UCB 
sample, although they could be used for 
other clinical purposes, which may, as the 
defenders of the creation of private UCB 
banks suggest, extend their possibility for 
use. Hypothetically, the highest likelihood 
of using these samples is in the field of 
regenerative and reparatory medicine, 
since it has already been possible to 
confirm the transdifferentiation of UCB 
stem cells to brain, heart, liver, pancreas, 
bone and cartilage cells72,73.
Thus autologous UCB, rich in adult 
stem cells, could be used by the patient 
themselves or by a relative to try to 
regenerate a damaged organ74,75,76,77. 
72 Porada GA, Porada C, Zanjani ED. «The 
fetal sheep: a unique model system for assessing the 
full differentiative potential of human stem cells» 
Yonsei Medical Journal 45(suppl), (2004), 7-14.
73 Kogler G. «A new human somatic stem cell 
from placental cord blood with intrinsic pluripotent 




76 Cord blood Registry (online) http://www.
cordblood.com/ (2007).
77 Ballen KK, Barker JN, Stewart SK et al. «Co-
llection and preservation of cord blood for personal 
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However, this is a possibility that has 
yet to be confirmed, although given the 
many clinical trials currently underway 
with adult stem cells (around 3417) and 
UCB (around 196)78, it does not appear to 
be an exaggeration to think that for the 
child donating the cord blood or for some 
of their relatives, the stem cells contained 
in it could be useful in the mid- to long-
term to treat possible tissues that might 
require reparatory treatment. 
Moreover, given that UCB contains 
mesenchymal cells79 from which cells 
of various tissues, such as bone, fat and 
cartilage have been able to be derived80, 
this would extend its possible use to 
relatives, within the aforementioned 
field of regenerative and reparatory 
medicine81. In addition to mesenchymal 
cells, UCB also contains endothelial 
progenitor cells82,83, which can specifically 
be used to repair damaged blood vessels. 
use». Biology of Blood and Marrow Transplantation 14, 
(2008), 356-363.
78 Clinical trials http://clinicaltrials.gov (acces-
sed 06-07-11)
79 Bieback K, Klüter H «Mesenchymal stromal 
cells from umbilical cord blood» Current Stem Cell 
Research and Therapy 2, (2007), 310-323. 
80 Bianco P, Robey PG, Simmons PJ «Mesen-
chymal Stem Cells: Revisiting History, Concepts, 
and Assays» Cell Stem Cell 2, (2008), 313-319.
81 Uccelli A, Moretta L, Pistoia V «Mesenchy-
mal stem cells in health and disease» Nature Reviews 
Immunology 8, (2008), 726-736.
82 Au P, Daheron LM, Duda DG et al. «Diffe-
rential in vivo potential of endothelial progenitor 
cells from human umbilical cord blood and adult 
peripheral blood to form functional long-lasting 
vessels» Blood 111, (2008), 1302-1305.
83 Prockop DJ. «Repair of tissues by adult 
stem/progenitor cells (MSCs): controversies, myths, 
and changing paradigms» Molecular Therapy 17, 
(2009), 939-946.
Nevertheless, there is still a long way to 
go in this area before its possible clinical 
application84.
Finally, an additional possibility for 
the use of UCB stem cells would be to 
use them to generate the patient’s own 
iPS cells (reprogrammed adult cells), from 
which cells of different tissues could be 
derived, theoretically increasing their 
possibility for clinical use85,86. However, for 
iPS cells derived from UCB cells to become 
an objective clinical reality, a series of 
unavoidable technical problems must first 
be resolved so that this step can be taken87.
3.3. Other reasons for sustaining the ethical 
controversy between public and private UCB 
banks
In addition to the aforementioned 
reasons, possibly the main ethical reason 
which does not support setting up 
autologous UCB banks is that promoting 
them could go against a generic principle 
of social solidarity, on reserving the 
samples stored in them for the exclusive 
use of the donor or their family88. This 
84 Prockop DJ, op. cit. 83.
85 Haase A, Olmer R, Schwanke K et al. «Ge-
neration of induced pluripotent stem cells from 
human cord blood» Cell Stem Cell 5:, (2009), 434-441.
86 Giorgetti A, Montserrat N, Aasen T et al. 
«Generation of induced pluripotent stem cells from 
human cord blood using OCT4 and SOX2» Cell Stem 
Cell 5, (2009), 353-357.
87 Saha K, Jaenisch R «Technical challenges 
in using human induced pluripotent stem cells to 
model disease» Cell Stem Cell 5, (2009), 484-595.
88 American College of Obstetricians and 
Gynecologists «Committee opinion, umbilical cord 
blood banking.» Obstetrics and Gynecology 111, 
(2008), 475-477.
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Another ethical difficulty related with 
the generic principle of social justice 
could arise as there are women who, 
even though they wish to donate the 
UCB, cannot do so as in certain countries 
or regions there are no proper legal 
requirements or technical conditions 
necessary to obtain the sample.
The fact that samples to be stored 
in private banks (for financial reasons 
or profit) are not subject to the same 
technical controls as those stored in 
public banks could also pose an ethical 
problem, as it would probably mean that 
autologous UCB samples stored in private 
banks would be of lower quality than 
those stored in public banks89. 
As we have previously stated, 
according to data from the Spanish 
Ministry of Health90, between 50% and 
80% of samples are discarded in Spain as 
they do not meet the technical suitability 
specifications required for storage. Are 
we certain that this is not also the case 
with the autologous UCB samples to 
be stored in private banks? Are there 
data relating to the number of samples 
that are rejected as they do not have 
the appropriate technical specifications? 
We believe that this rejection, which for 
unquestionable financial reasons does 
not occur, would certainly constitute an 
ethically unacceptable medical act.
89 Sun J, Allison J, Mc Laughlin C et al. «Di-
fferences in quality between privately and publicly 
banked umbilical cord blood units: a pilot study 
of autologous cord blood infusion in children with 
acquired autologous disorders.»Transfusion 50, 
(2010), 1980-1987.
90 Ibid 39.
ethical diatribe has its basis in the search 
for a balance between social solidarity 
and individual liberties. Indeed, for those 
who defend the promotion of public UCB 
banks, a fundamental ethical principle 
to consider is that any individual free 
decision should be respectful of a generic 
principle of social justice. Nevertheless, 
those who are in favour of the promotion 
of private autologous UCB banks believe 
that controversy cannot be raised between 
individual liberties and social solidarity, 
since not all free action should be subject 
to the principle of solidarity, although 
it would be desirable, since solidarity 
should be exercised freely. This is 
based on their opinion that individual 
liberties are above solidarity, a statement 
which, although reasonable, does not 
obviate that on occasion the lack of 
social solidarity conditions the ethical 
assessment of individual actions carried 
out freely, since if this principle were 
admitted as an absolute in relation to the 
creation of private UCB banks, it could 
lead to uncontrolled growth of private 
autologous UCB banks to the detriment 
of public banks. This could infringe on 
the principle of social solidarity to which 
we are referring, especially if we take 
into account the marked individualism 
that currently predominates our Western 
civilisation.
On the other hand, it can be stated 
that public banks, as they are financed 
with state funds, guarantee the possibility 
of addressing the health issues of all 
citizens, thus honouring the right of all 
people to health, one of the fundamental 
human rights.
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This potentially deceptive information 
extends to offering lists of possible 
diseases that can be treated with UCB, 
including cancer, bone marrow failures 
and genetic diseases, without there being 
medical evidence for this to date, as most 
of these diseases can only be treated with 
allogeneic UCB transplants. Equally, 
most commercial banks also offer the 
possibility of using autologous UCB 
for numerous diseases which could be 
treated in the future within the field of 
regenerative and reparatory medicine93, 
although as has already been mentioned, 
this is still a hypothetical possibility far 
from having been confirmed. A positive 
exception in this turbulent field of private 
UCB banks may be the Virgin Health 
Bank, which as will be discussed later, 
offers a mixed solution and true and clear 
information94.
3.4. Alternatives to the use of private banks
A possible alternative to make the 
conservation of autologous blood in 
private banks more ethical is the proposal 
by the English Virgin Health Bank95,96, 
in which 80% of the sample stored is 
reserved for allogeneic public use and 
20% for private autologous use. The 
aforementioned proposal has, at present, 
the disadvantage that the 20% reserved for 
93 Manegold G, Meyer-Monard S, Tischelli A 
et al. op. cit. 58.
94 Editorial «Umbilical cord blood banking 
Richard Branson’s way» The Lancet 369, (2007), 437.
95 op. cit. 94.
96 Mayor S «World’s first public-private cord 
blood bank launched in UK by Richard Branson» 
British Medical Journal 334, (2007), 277.
Another ethical question that can 
be posed is whether offering medical 
services that require a high financial 
investment for the users to utilise them 
several years later (on occasions more 
than fifteen) can be accepted without 
taking into account the possible risk that 
the companies that offer those services, 
proprietors of the autologous UCB banks, 
may terminate their activity due to 
company circumstances of any type. Thus 
the European Group for Ethics in Science 
and New Technologies recommends that 
given the possibility of these companies 
closing, it should be mandatory to 
provide clients with information about 
this possible eventuality, and insurance 
should guarantee the continuity of sample 
storage or the power to transfer them to 
another bank, in addition to compensating 
the clients adequately if necessary91.
Finally, another important point to 
take into consideration is whether private 
banks offer adequate information to their 
potential clients about all the medical and 
ethical aspects related with the collection 
and storage of UCB samples. In relation 
to this, a systematic review of web pages 
published in English including data from 
148 commercial banks confirmed that the 
information given to clients is, on many 
occasions, confusing and potentially 
erroneous, possibly motivated by the 
financial benefits to be obtained92.
91 European Group on Ethics in Science and 
New Technologies to the European Commission. 
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allogeneic transplant, following parental 
consent.
3.5. Ethical opinion that umbilical cord banks 
merit different public institutions or scientific 
bodies
In general we can state that, in view 
of the above, expert groups, public 
authorities and opinion leaders are not in 
favour of the promotion of private UCB 
banks100,101,102. 
Hence, the European Group on Ethics 
in Science and New Technologies states 
that commercial banks merit serious ethical 
reservations103. Equally, the Convention of 
Oviedo (article 21) is reluctant to store 
autologous UCB as it states that «the 
human body and its parts shall not give 
rise to financial gain» 104. The World 
Association of Bone Marrow Donors 
also questions autologous UCB banks, as 
they offer a service that, at present, does 
not have real therapeutic use and often 
«promises more than they can deliver»105. 
Among the scientific institutions, 




103 op. cit 91.
104 Convention for the protection of human 
rights and dignity of the human being with regard 
to the application of biology and medicine: Con-
vention on human rights and biomedicine, Oviedo; 
4 April 1997 http://conventions.coe.int/Treaty/en/
Treaties/Html/164.htm
105 WMDA policy statement on the utility of 





autologous use may not be sufficient to 
meet its therapeutic objective. However, 
to resolve this limitation, scientists 
are actively working, as are Virgin, 
on the development of cell expansion 
techniques97,98 that may increase the 
cellularity of the samples to thereby make 
them clinically useful. Richard Branson, 
proprietor of Virgin Bank, donates 50% of 
the profits from Virgin Bank to research 
aimed at increasing the therapeutic 
potential of UCB99.
Some countries, among them Spain, 
offer the possibility of conserving the 
autologous sample in a public bank, but 
with the condition that if at a determined 
moment said sample should be required 
for a patient unrelated to the donor’s 
family, there would be a legal obligation 
to give it to them. Thus, there would be 
the risk that the autologous blood that 
was conserved for the priority use of the 
donor or their family would be unable 
to fulfil its purpose on having been used 
by another patient. However, if this risk 
is voluntarily accepted, mixed public 
banks could be considered ethically 
acceptable, although it would have to 
be guaranteed that the blood conserved 
in them is properly typed so that, where 
appropriate, it could be assigned for an 
97 Jaroscak J, Goltry K, Smith A et al «Aug-
mentation of umbilical cord blood (UCB) transplan-
tation with ex vivo-expanded UCB cells: results of 
a phase 1 trial using the Aastrom Replicell System» 
Blood 101, (2003), 5061-5067.
98 Delaney C, Heimfeld S, Brashem-Stein C 
et al «Notch-mediated expansion of human cord 
blood progenitor cells capable of rapid myeloid 
reconstitution» Nature Medicine 16, (2010), 232-236.
99 Mayor S, op.cit. 96.
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The Italian Ministry for Health and 
Social Policy, in a report on the proper 
use of UCB stem cells115, also stated that: 
«the indications for the conservation of 
UCB at birth, with a view to a future 
autologous haematopoietic transplant are 
non-existent for the moment», having «at 
present actual scientific evidence only for 
the use of allogeneic blood».
4. General ethical aspects related with 
the donor and her child
Regardless of the ethical aspects 
specifically related to the promotion, 
development and maintenance of UCB 
banks, certain general ethical regulations 
should be taken into consideration on 
discussing the ethics of these banks, since 
the donation of UCB samples should 
be given the same ethical treatment as 
the donation of organs and tissues for 
biomedical research.
Since this is not the specific aim of 
this report, we will refer to the general 
ethical aspects following two recent, well-
structured reviews116,117. In agreement with 
that stated therein, informed consent, the 
obtaining of financial benefits, ownership 
implications for perinatal care providers» Journal of 
Obstetrics and Gynaecology Canada 27, (2005), 263-290.
115 Ibid 28.
116 American Medical Association. (presented 
by: Levine Mark A) Umbilical cord blood banking. 
Report of the Council on Ethical and Judicial Affairs. 
American Medical Association. CEJA Report 9-I-
07. November 2007 www.ama_assn.org/ama/pub/
physician-resources/medical-ethics/code-medical-
ethics/opinion2165.shtml
117 Petrini C «Umbilical cord blood collection, 
storage and use: ethical issues» Blood Transfusion 8, 
(2010), 139-148.
Obstetricians and Gynaecologists is also 
opposed to the creation of private UCB 
banks for ethical and medical reasons106, 
as is the Royal College of Midwives107. 
Similarly, the Belgian Advisory Committee 
on Bioethics Opinion108, the Swiss Society 
of Gynaecology and Obstetrics109 and 
the French Academy of Medicine110 
do not advocate private banks. The 
American Academy of Pediatrics111,112, 
the American College of Obstetricians 
and Gynecologists113 and the Society 
of Obstetricians and Gynaecologists of 
Canada114 also agree in this respect.
106 Royal College of Obstetricians and Gy-
naecologists. Scientific advisory committee opinion 
paper 2, Umbilical cord blood banking; June 2006 
http://www.rcog.org.uk/files/rcog-corp/uploaded-
files/SAC2UmbilicalCordBanking2006.pdf
107 Royal College of Midwives. «Guidance 
Paper 1a: commercial umbilical cord blood collec-
tion.» RCM Midwives 5, (2002), 422-423.
108 Belgian Advisory Committee on Bioethics 
Opinion Nº 42 of 16 April 2007 on umbilical cord 
blood banks.
109 Surbek D, Seelmann K, Gratwohl A et 
al Société Suisse de Gynécologie and Obstétrique. 
«Don de sang de cordon: Don non dirigé, don 
familial (dirigé) et don à but de transplantation 
autologue («Private banking»)» Avis d’Experts Nº 
10, Décembre 2002 http://sggg.ch/files/AVIS%20
%D%20EXPERTS2010.pdf
110 Bourel M, Arcadillou R Rapport: Les 
banques de sang de cordon autologue. Académie 
Nationale de Médecine 19 November 2002
111 American Academy of Pediatrics. «Cord 
blood banking for potential future transplantation.» 
Pediatrics 1, (2007), 165-170.
112 American Academy of Pediatrics WGOCBB 
«Cord blood banking for potential future trans-
plantation: subject review American Academy of 
Pediatrics. Work group on cord blood banking.» 
Pediatrics 104, (1999), 116-118.
113 Ibid 88.
114 Armson BA Maternal/fetal medicine 
committee, Society of Obstetricians and Gynaeco-
logists of Canada. «Umbilical cord blood banking: 
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since some people advocate that it is 
property of the child, as it is a part of 
their body, and others believe that it 
should be property of the mother. The 
first position appears to be more correct 
given that, in most developed countries, 
the child who is fully outside the mother 
is legally recognised as a person, with all 
the rights inherent to this condition, so 
the manipulation of part of their body 
should be considered as a violation of 
their principle of autonomy.
Finally, special caution should be 
taken in any relationships that health care 
workers responsible for advocating and 
obtaining the sample may have with the 
private banks in which the UCB is to be 
deposited, to prevent possible financial 
gains which could cloud their medical 
actions, if they encourage the woman to 
bank the sample in private banks with 
which they collaborate.
5. Conclusions
Many criticisms have been made of the 
establishment of private UCB banks from 
an ethical point of view, as expressed 
here. However, in our opinion, there is no 
definitive ethical argument why a couple 
cannot bank the umbilical cord blood of 
any of their children in one of these banks, 
invoking their right to exercise their 
autonomy and personal freedom. This 
right is reinforced by the medical reality 
that the best clinical response is obtained 
using the blood from a close relative or 
the patient themselves. Furthermore, the 
fact that autologous blood also offers the 
possibility of being used in the field of 
of the stored samples,data storage and the 
privacy of the donor and her child would 
have to be considered among others.
Obtaining informed consent from 
the woman donating the UCB sample 
is fundamental to ensure her autonomy. 
Said consent should be obtained prior to 
the onset of labour, so that the woman 
is in the best condition to be able to give 
that consent with full awareness.
The report given to the woman to sign 
would have to include the method to be 
followed to obtain the sample, how it 
is to be handled after it is obtained and 
the choice of banks available to store it, 
as well as the risk that, due to various 
medical circumstances, the UCB cannot 
be stored as it is not of sufficient quality.
In relation to data storage and 
protection, the existing regulations in 
most developed countries would have 
to be respected.
With regard to the protection of the 
privacy of the mother donating the UCB 
and her child, the same precautions 
would have to be taken as with blood 
samples obtained for any other medical 
purpose.
Another ethical aspect to consider is 
whether the relationship between the 
UCB bank where the sample is banked 
and the women who donate it should be 
maintained, as this could be useful in the 
eventual subsequent use of the conserved 
blood, although this relationship would 
have to be treated with consummate 
care, as there may be a risk of violating 
confidentiality, both mother’s and child’s.
The ownership of the stored UCB 
sample also merits a legal reflection, 
285Cuad. Bioét. XXIII, 2012/2ª
Umbilical cord blood banks. Ethical aspects. Public vs. private banks
public banks more adequately meet the 
medical and ethical purposes for which 
they are intended, on guaranteeing their 
use for all citizens, thereby fulfilling a 
positive principle of justice and social 
solidarity.
With respect to private companies 
that promote the creation of umbilical 
cord blood banks, we believe that the 
same ethical regulations can be applied, 
i.e. that there are no determinant reasons 
to prevent them from exercising their 
commercial action freely, but always 
respecting the unavoidable precept of 
informing their clients of the limited 




regenerative and reparatory medicine by 
the patient themselves or a close relative 
may also open up further potential 
for use. Nevertheless, despite this, the 
possibilities of using an autologous blood 
sample are remote, a fact of which parents 
who wish to conserve the umbilical cord 
blood of their child should be made 
aware.
In summary, our opinion is that from 
an ethical point of view, promoting the 
creation of public umbilical cord blood 
banks is the ideal solution, but in a strict 
sense there does not appear to be any 
insurmountable ethical reason why some 
parents cannot opt to bank the blood of 
their child in a private bank, although 
always leaving it well established that 

